On December 24, 2021 Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) reported that HB0030 (anti-TIGIT monoclonal antibody) completed the first-in-human administration in China at the First Affiliated Hospital of Bengbu Medical College (Press release, Huabo Biopharm, DEC 24, 2021, View Source [SID1234656057]). This is an open label, single-center, dose-escalation Phase Ia clinical study in order to assess the safety and pharmacokinetics in patients with advanced solid tumors. The main The purpose of the study is to comprehensively evaluate the safety, tolerability and antitumor activity of HB0030 in patients with advanced malignant solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
About TIGIT
TIGIT, T cell immune receptor with Ig and ITIM domains, is an inhibitory receptor expressed on lymphocytes belonging to the Ig superfamily with multi-characteristic structure of immunoregulatory proteins including CD96 and CD226. They interact with Nectin and nectin-like molecules with different affinities.
TIGIT, CD226, CD96 and their ligands CD155 and CD11 form a complex regulatory network. As TIGIT/CD155 deliver the immunosuppressive signal, CD155 interaction with CD226 deliver an immunostimulating signal. The CD155 and CD112 are highly expressed on the surface of many malignant tumors, such as colorectal cancer and melanoma.
About HB0030
HB0030 is a humanized monoclone antibody designed by Huaota Biopharm to bind TIGIT with high-affinity, thereby blocking the binding of TIGIT to its ligand (such as CD155). By binding to TIGIT, highly expressed on the surface of T cells and NK cells, HB0030 blocks its interaction with CD155, relieves immunosuppression and reactivate the tumor-killing effect of T cells and NK cells.
Preclinical studies have shown that HB0030 has higher affinity and strong ADCC/CDC activity. It can relieve the T-cell immunosuppression and enhance the anti-tumor activity.